TB-500 in 2026: What It Is, Why It's Not Available Clinically, and What the Alternatives Are
TB-500 is a synthetic peptide fragment of thymosin beta-4, an actin-sequestering protein found throughout the body. It has been studied in preclinical models for effects on cell migration, angiogenesis, and tissue signaling. Like BPC-157, TB-500's evidence base is primarily preclinical — large-scale human clinical trials do not exist.
TB-500 was placed on the FDA Category 2 list of bulk substances posing significant safety risks in late 2023, prohibiting it from 503A compounding. As of this page's publication, TB-500 is NOT FDA-approved, NOT available through licensed 503A compounding pharmacies, and NOT legitimately available through any clinical channel in the US.
We are publishing this page for educational context only. We do not recommend TB-500 use, we do not link to research-chemical vendors regardless of their RUO disclaimers, and we do not publish dosing protocols. If you are interested in the tissue-signaling indications TB-500 is researched for, the appropriate next step is a clinician conversation about legitimate alternatives.
- 10 programs ranked
- Editor-reviewed
- Reader-verified
- Updated weekly
What's actually available: TB-500 samples in 2026
Three paths for people typing “tb-500samples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Talk to a peptide-friendly clinician | Marek Health, Defy Medical, Eden, AgelessRx, GobyMeds — clinical conversation about legitimate alternatives. | Varies by clinic; consult fees $150-500 | Patients interested in the indications TB-500 is researched for, seeking a legitimate clinical path |
| GHK-Cu (clinical alternative for tissue support) | 503A-compounded copper peptide with decades of post-market history. | $80-300 per vial | Patients seeking tissue-signaling support through a clean regulatory path |
| Direct TB-500 acquisition | We do not provide guidance on TB-500 acquisition or recommend any vendor. | N/A | N/A — see clinical alternatives above |
How TB-500 samples actually work
What thymosin beta-4 is and how TB-500 differs
Thymosin beta-4 is a 43-amino-acid actin-sequestering protein found in nearly every cell type. It plays roles in cell motility, tissue signaling, and angiogenesis. TB-500 is a synthetic peptide fragment containing the bioactive sequence of thymosin beta-4. The fragment was developed for research because it retains many of the parent molecule's signaling activities in a smaller, more synthesizable peptide. The full thymosin beta-4 protein has been studied clinically in some indications; TB-500 specifically has not.
Why TB-500 marketing pairs with BPC-157
Vendor marketing frequently positions TB-500 and BPC-157 as complementary 'recovery stack' peptides. Both share preclinical mechanism research suggesting effects on tissue signaling and angiogenesis. Both share the same regulatory posture: Cat-2 listed, prohibited from 503A compounding, sold only via research-chemical vendor channels. The 'stack' marketing language is real; the legitimate clinical pathway is not.
Why we don't link to TB-500 vendors
Same logic as BPC-157. TB-500 is sold by research-chemical vendors with 'Research Use Only' disclaimers. The April 2026 FDA enforcement action against 7 peptide RUO vendor sites clarified that RUO labeling does not protect vendors from drug-misbranding charges. Linking to those vendors creates downstream regulatory exposure for our readers. We treat the no-vendor-link rule as absolute on educational-track pages.
TB-500 is the BPC-157 of cell-migration research peptides — substantial preclinical interest, no human clinical pathway in the US, vendor marketing that overstates the human evidence base.
TB-500 cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Clinician consultation about alternatives | $150-500 | Varies by chosen alternative | First step for any patient interested in the indications TB-500 is researched for. |
| GHK-Cu via 503A pharmacy | $200-500 | $80-300 / vial | Closest legitimate clinical alternative for tissue-signaling indications. |
| Sermorelin + ipamorelin combo | $99-149 | $99-249 / mo | Different mechanism (GH secretagogue) but adjacent clinical use case for recovery support. |
What to expect on TB-500: your first weeks
We do not provide TB-500 acquisition guidance.
If you are interested in the indications TB-500 is researched for, the appropriate next step is a clinician consultation.
Marek Health, Defy Medical, Eden, AgelessRx, and GobyMeds support this conversation.
Clinical evidence behind TB-500
TB-500's evidence base is primarily preclinical — animal models and in-vitro studies of cell migration, tissue signaling, and angiogenesis. Human clinical trials at phase-2 or phase-3 scale specifically of the TB-500 fragment do not currently exist. Some research on the parent molecule (full thymosin beta-4) exists in a wound-healing context. We do not endorse vendor marketing claims about TB-500's effects in humans.
TB-500side effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •We do not publish side-effect or safety information on TB-500 use because we do not endorse use outside an investigational context.
- •If you are considering TB-500 use, the appropriate source for safety information is a clinician with peptide expertise, not vendor marketing.
- •Talk to Marek Health, Defy Medical, Eden, AgelessRx, or GobyMeds before making any decisions.
Who shouldn't take TB-500
- •Anyone seeking TB-500 outside an investigational research context — the molecule has no legitimate clinical pathway in the US.
- •Patients who would prefer a legitimate clinical alternative for tissue-support indications — see GHK-Cu or the GHRH + GHRP combo.
Eligibility for TB-500
- •We do not provide eligibility guidance for TB-500.
- •If you are interested in the indications TB-500 is researched for, the appropriate next step is a clinician consultation about legitimate alternatives.
- •See the GHK-Cu, sermorelin, or ipamorelin pages for legitimate clinical paths.
TB-500 samples: frequently asked
Why won't you link to TB-500 vendors?
Same logic as BPC-157. TB-500 is sold by research-chemical vendors with 'Research Use Only' disclaimers. The April 2026 FDA enforcement action against 7 RUO peptide vendor sites clarified that RUO labeling does not protect against drug-misbranding charges when marketing context implies human use. Linking to those vendors creates downstream regulatory exposure for our readers.
Is TB-500 the same as full thymosin beta-4?
No. TB-500 is a synthetic peptide fragment containing a bioactive sequence of thymosin beta-4. The full thymosin beta-4 protein is 43 amino acids; TB-500 is a smaller fragment. Some research on the parent molecule exists; large-scale clinical research on the TB-500 fragment specifically does not.
What's the closest legitimate alternative to TB-500?
GHK-Cu is the closest clinical alternative with a clean regulatory path for tissue-signaling indications. For broader recovery and tissue-support, GHRH + GHRP combos (sermorelin + ipamorelin, or CJC-1295 + ipamorelin) are worth discussing with a clinician.
Why do BPC-157 and TB-500 always appear together in marketing?
Both share preclinical mechanism research in tissue signaling and angiogenesis. Vendor marketing positions them as complementary 'recovery stack' peptides. Both share identical US regulatory posture (Cat-2 listed, no clinical channel) and identical evidence-base limitations (preclinical only).
Will TB-500 ever become FDA-approved or available via 503A?
Unlikely in the near term. Same regulatory situation as BPC-157 — new-drug FDA approval requires a sponsor and a phase-3 trial program; removal from Cat-2 requires PCAC review which has not occurred since the 2023 listing.